|
시장보고서
상품코드
1452576
유럽의 분자진단 시장 전망(-2030년) : 지역별 분석 - 질환별, 기술별, 제품/서비스별, 최종사용자별, 지역별 시장 예측Europe Molecular Diagnostics Market Forecast to 2030 - Regional Analysis - by Disease Area, Technology, Product and Services, and End User |
||||||
유럽의 분자진단 시장은 2022년 45억 9,254만 달러에서 2030년 112억 2,577만 달러로 성장할 것으로 예상되며, 2022-2030년간 연평균 11.8%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.
관련 질환의 급증으로 유럽의 분자진단 시장 활성화
분자진단법은 종양성 질환, 감염성 질환, 심장 질환, 면역계 질환 등 다양한 질환을 진단하는 데 사용할 수 있습니다. 또한 DNA, RNA 등 유전물질을 이용한 유전자 검사에도 사용할 수 있어 다양한 질병을 진단할 수 있습니다. 암은 전 세계적으로 주요 사망 원인 중 하나입니다. UK.GOV가 2021년 11월 22일 발표한 자료에 따르면, 코로나19의 감염률은 인구 10만 명당 422.7명으로, 암을 조기에 발견하면 환자의 사망을 예방할 수 있습니다. 이처럼 대상 질환의 유병률 증가는 분자진단 시장의 성장을 가속하고 있습니다.
유럽의 분자진단 시장 개요
유럽의 분자진단 시장은 독일, 영국, 프랑스, 이탈리아, 스페인, 기타 유럽으로 구분됩니다. 이 지역은 전 세계 분자진단 시장에서 큰 비중을 차지하고 있으며, 2022-2030년까지 견조한 CAGR을 나타낼 것으로 예상됩니다. 유럽 시장 성장은 생명과학 연구의 성장과 감염성 질환 검사에 대한 정부의 투자 증가에 기인합니다.
만성폐쇄성폐질환(COPD), 당뇨병, 암, 관절염과 같은 만성질환은 방치하면 생명을 위협할 수 있습니다. 예를 들어, 만성 림프성 백혈병(CLL)은 독일에서 가장 흔한 백혈병의 일종으로, Deutsches Arzteblatt에 따르면 독일에서 CLL의 유병률은 10만 명당 6건 정도이며, 매년 약 850명의 여성과 1,000명의 남성이 CLL로 사망하고 있습니다.
유럽의 분자진단 시장 매출 및 2030년까지의 예측(금액)
유럽의 분자진단 시장 세분화
유럽의 분자진단 시장은 질병 영역, 기술, 제품 및 서비스, 최종 사용자, 국가별로 분류됩니다.
질병 분야별로 보면, 유럽의 분자진단 시장은 감염, 종양, 유전자 검사, 심장질환, 면역계 질환, 기타로 구분됩니다. 감염병 분야는 2022년 유럽의 분자진단 시장에서 가장 큰 점유율을 기록했습니다.
기술별로 유럽의 분자진단 시장은 중합효소 연쇄반응(PCR), In situ hybridization, 등온 핵산 증폭 기술(INAAT), DNA 시퀀싱 및 차세대 시퀀싱(NGS), DNA 마이크로어레이, 기타로 나뉩니다. 중합효소연쇄반응(PCR) 부문은 2022년 유럽의 분자진단 시장에서 가장 큰 점유율을 기록했습니다. 중합효소연쇄반응(PCR)은 RT-PCR, qPCR, 멀티플렉스 PCR, 기타로 세분화됩니다.
제품 및 서비스를 기준으로 유럽의 분자진단 시장은 분석 및 키트, 기기, 서비스 및 소프트웨어로 구분되며, 2022년 유럽의 분자진단 시장 점유율은 분석 및 키트 분야가 가장 컸습니다.
최종 사용자별로 유럽의 분자진단 시장은 진단 실험실, 병원 및 클리닉, 연구 및 학술 기관, 기타로 구분됩니다. 진단 실험실 부문은 2022년 유럽의 분자진단 시장에서 가장 큰 점유율을 차지했습니다.
국가별로는 유럽의 분자진단 시장은 독일, 영국, 프랑스, 이탈리아, 스페인, 기타 유럽으로 분류되며, 2022년 유럽의 분자진단 시장은 독일이 독식할 것으로 예상됩니다.
Abbott Laboratories, Agilent Technologies Inc, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Qiagen NV, bioMerieux SA, Illumina Inc, Danaher, Siemens Healthineers AG, Novartis AG 등이 유럽의 분자진단 시장에 진출한 주요 기업들입니다.
목차
제1장 서론
제2장 주요 요약
- 주요 인사이트
제3장 조사 방법
- 조사 범위
- 2차 조사
- 1차 조사
제4장 유럽의 분자진단 시장 구도
- 개요
- PEST 분석
- 유럽 PEST 분석
제5장 유럽의 분자진단 시장 역학 : 주요 산업 역학
- 주요 시장 성장 촉진요인
- 시장 성장 억제요인
- 시장 기회
- 향후 동향
- 영향 분석
제6장 분자진단 시장 - 유럽 시장 분석
- 유럽의 분자진단 시장 매출, 2022년-2030년
제7장 유럽의 분자진단 시장 : 매출과 2030년까지 예측 - 질환 영역별
- 시장 매출 점유율(%), 2022년 및 2030년
- 종양학
- 감염증
- 유전자 검사
- 심장 질환
- 면역계 질환
- 기타
제8장 유럽의 분자진단 시장 : 매출과 2030년까지 예측 - 기술별
- 시장 매출 점유율(%), 2022년 및 2030년
- 중합효소 연쇄반응
- 등온 핵산 증폭 기술(INAAT)
- DNA 시퀀싱과 차세대 시퀀싱(NGS)
- DNA 마이크로어레이
- In-Situ Hybridization(ISH)
- 기타
제9장 유럽의 분자진단 시장 : 매출과 2030년까지 예측 - 제품 및 서비스별
- 시장 매출 점유율(%), 2022년 및 2030년
- 어세이 및 키트
- 기기
- 서비스 및 소프트웨어
제10장 유럽의 분자진단 시장 : 매출과 2030년까지 예측 - 최종사용자별
- 시장 매출 점유율(%), 2022년 및 2030년
- 병원 및 진료소
- 진단 실험실
- 연구 및 학술기관
- 기타
제11장 유럽의 분자진단 시장 : 국가별 분석
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
제12장 유럽의 분자진단 시장 : 업계 상황
- 시장 진출기업의 성장 전략(%)
- 유기적 전개
- 무기적 개발
제13장 유럽의 분자진단 시장, 주요 기업 개요
- Abbott Laboratories
- Agilent Technologies Inc
- Thermo Fisher Scientific Inc
- F. Hoffmann-La Roche Ltd
- Qiagen NV
- bioMerieux SA
- Illumina Inc
- Danaher
- Siemens Healthineers AG
- Novartis AG
제14장 부록
LSH 24.04.29The Europe molecular diagnostics market is expected to grow from US$ 4,592.54 million in 2022 to US$ 11,225.77 million by 2030. It is estimated to grow at a CAGR of 11.8% from 2022 to 2030.
Surging Prevalence of Associated Diseases Fuels Europe Molecular Diagnostics Market
Molecular diagnostics procedures can be employed in the detection of a wide range of conditions such as oncologic diseases, infectious diseases, cardiac diseases, and immune system disorders; they can also be used in genetic testing using genetic material such as DNA and RNA for the diagnosis of different diseases. Cancer is one of the leading causes of death worldwide. The early detection of the disease can help prevent death among the patients. According to the data published by the UK.GOV on November 22, 2021, the infection rate of COVID-19 was ~422.7 per 100,000 population. Thus, the rising prevalence of target diseases fuels the molecular diagnostics market growth.
Europe Molecular Diagnostics Market Overview
The European molecular diagnostics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant share of the global molecular diagnostics market and is expected to register a robust CAGR during 2022-2030. The market growth in Europe is attributed to growing life science research and an increase in government investment in testing infectious diseases.
Chronic diseases such as chronic obstructive pulmonary disease (COPD), diabetes, cancer, and arthritis can be life-threatening if left untreated. For instance, chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Germany. According to the Deutsches Arzteblatt, the prevalence of CLL in Germany stands at ~6 cases per 100,000; nearly 850 women and 1,000 men die from CLL every year.
Europe Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Million)
Europe Molecular Diagnostics Market Segmentation
The Europe molecular diagnostics market is segmented into disease area, technology, product and services, end user, and country.
Based on disease area, the Europe molecular diagnostics market is segmented into infectious disease, oncology, genetic testing, cardiac diseases, immune system disorders, and others. The infectious disease segment registered the largest Europe molecular diagnostics market share in 2022.
Based on technology, the Europe molecular diagnostics market is segmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), DNA sequencing and next-generation sequencing (NGS), DNA microarrays, and others. The polymerase chain reaction (PCR) segment registered the largest Europe molecular diagnostics market share in 2022. The polymerase chain reaction (PCR) is further sub segmented into RT-PCR, qPCR, multiplex PCR, and others.
Based on product and services, the Europe molecular diagnostics market is segmented into assays and kits, instruments, and services and software. The assays and kits segment registered the largest Europe molecular diagnostics market share in 2022.
Based on end users, the Europe molecular diagnostics market is segmented into diagnostic laboratories, hospitals and clinics, research and academic institutes, and others. The diagnostic laboratories segment held the largest Europe molecular diagnostics market share in 2022.
Based on country, the Europe molecular diagnostics market has been categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe molecular diagnostics market in 2022.
Abbott Laboratories, Agilent Technologies Inc, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Qiagen NV, bioMerieux SA, Illumina Inc, Danaher, Siemens Healthineers AG, and Novartis AG are some of the leading companies operating in the Europe molecular diagnostics market.
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
- 2.1 Key Insights
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. Europe Molecular Diagnostics Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
- 4.2.1 Europe PEST Analysis
5. Europe Molecular Diagnostics Market - Key Industry Dynamics
- 5.1 Key Market Drivers:
- 5.1.1 Development of New Products and Increase in Demand for Point-of-Care Testing
- 5.1.2 Surging Prevalence of Associated Diseases
- 5.2 Market Restraints
- 5.2.1 Limitations Associated with Molecular Testing
- 5.3 Market Opportunities
- 5.3.1 Advancements in Molecular Diagnostics Technologies
- 5.4 Future Trends
- 5.4.1 Molecular Diagnostics in Personalized Medicine
- 5.5 Impact Analysis:
6. Molecular Diagnostics Market - Europe Market Analysis
- 6.1 Europe Molecular Diagnostics Market Revenue (US$ Mn), 2022 - 2030
7. Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 - by Disease Area
- 7.1 Overview
- 7.2 Europe Molecular Diagnostics Market Revenue Share, by Disease Area 2022 & 2030 (%)
- 7.3 Oncology
- 7.3.1 Overview
- 7.3.2 Oncology: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 7.4 Infectious Disease
- 7.4.1 Overview
- 7.4.2 Infectious Disease: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5 Genetic Testing
- 7.5.1 Overview
- 7.5.2 Genetic Testing: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 7.6 Cardiac Diseases
- 7.6.1 Overview
- 7.6.2 Cardiac Diseases: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 7.7 Immune System Disorders
- 7.7.1 Overview
- 7.7.2 Immune System Disorders: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 7.8 Others
- 7.8.1 Overview
- 7.8.2 Others: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
8. Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 - by Technology
- 8.1 Overview
- 8.2 Europe Molecular Diagnostics Market Revenue Share, by Technology 2022 & 2030 (%)
- 8.3 Polymerase Chain Reaction
- 8.3.1 Overview
- 8.3.2 PCR: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3.2.1 RT-PCR
- 8.3.2.1.1 Overview
- 8.3.2.1 RT-PCR
- 8.3.3 RT-PCR: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3.3.1 qPCR
- 8.3.3.1.1 Overview
- 8.3.3.1 qPCR
- 8.3.4 qPCR: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3.4.1 Multiplex PCR
- 8.3.4.1.1 Overview
- 8.3.4.1 Multiplex PCR
- 8.3.5 Multiplex PCR: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3.5.1 Others
- 8.3.5.1.1 Overview
- 8.3.5.1 Others
- 8.3.6 Others: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 8.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
- 8.4.1 Overview
- 8.4.2 Isothermal Nucleic Acid Amplification Technology (INAAT): Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 8.5 DNA Sequencing and Next-Generation Sequencing (NGS)
- 8.5.1 Overview
- 8.5.2 DNA Sequencing and Next-Generation Sequencing (NGS): Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 8.6 DNA Microarrays
- 8.6.1 Overview
- 8.6.2 DNA Microarrays: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 8.7 In-Situ Hybridization (ISH)
- 8.7.1 Overview
- 8.7.2 In-Situ Hybridization (ISH): Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 8.8 Others
- 8.8.1 Overview
- 8.8.2 Others: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
9. Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 - by Product and Services
- 9.1 Overview
- 9.2 Europe Molecular Diagnostics Market Revenue Share, by Product and Services 2022 & 2030 (%)
- 9.3 Assays and Kits
- 9.3.1 Overview
- 9.3.2 Assays and Kits: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 9.4 Instruments
- 9.4.1 Overview
- 9.4.2 Instruments: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 9.5 Services and Software
- 9.5.1 Overview
- 9.5.2 Services and Software: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
10. Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 - by End User
- 10.1 Overview
- 10.2 Europe Molecular Diagnostics Market Revenue Share, by End User 2022 & 2030 (%)
- 10.3 Hospitals and Clinics
- 10.3.1 Overview
- 10.3.2 Hospitals and Clinics: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.4 Diagnostics Laboratories
- 10.4.1 Overview
- 10.4.2 Diagnostics Laboratories: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.5 Research and Academic Institutes
- 10.5.1 Overview
- 10.5.2 Research and Academic Institutes: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.6 Others
- 10.6.1 Overview
- 10.6.2 Others: Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
11. Europe Molecular Diagnostics Market - Country Analysis
- 11.1 Europe Molecular Diagnostics Market, Revenue and Forecast to 2030
- 11.1.1 Overview
- 11.1.1.1 Europe Molecular Diagnostics Market by Country
- 11.1.2 Germany
- 11.1.2.1 Overview
- 11.1.3 Germany: Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.4 Germany: Molecular Diagnostics Market, by Disease Area
- 11.1.5 Germany: Molecular Diagnostics Market, by Technology
- 11.1.5.1 Germany: Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
- 11.1.6 Germany: Molecular Diagnostics Market, by Product and Services
- 11.1.7 Germany: Molecular Diagnostics Market, by End User
- 11.1.8 UK
- 11.1.8.1 Overview
- 11.1.9 UK : Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.10 UK: Molecular Diagnostics Market, by Disease Area
- 11.1.11 UK: Molecular Diagnostics Market, by Technology
- 11.1.11.1 UK: Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
- 11.1.12 UK: Molecular Diagnostics Market, by Product and Services
- 11.1.13 UK: Molecular Diagnostics Market, by End User
- 11.1.14 France
- 11.1.14.1 Overview
- 11.1.15 France: Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.16 France: Molecular Diagnostics Market, by Disease Area
- 11.1.17 France: Molecular Diagnostics Market, by Technology
- 11.1.17.1 France: Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
- 11.1.18 France: Molecular Diagnostics Market, by Product and Services
- 11.1.19 France: Molecular Diagnostics Market, by End User
- 11.1.20 Italy
- 11.1.20.1 Overview
- 11.1.21 Italy: Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.22 Italy: Molecular Diagnostics Market, by Disease Area
- 11.1.23 Italy: Molecular Diagnostics Market, by Technology
- 11.1.23.1 Italy: Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
- 11.1.24 Italy: Molecular Diagnostics Market, by Product and Services
- 11.1.25 Italy: Molecular Diagnostics Market, by End User
- 11.1.26 Spain
- 11.1.26.1 Overview
- 11.1.27 Spain: Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.28 Spain: Molecular Diagnostics Market, by Disease Area
- 11.1.29 Spain: Molecular Diagnostics Market, by Technology
- 11.1.29.1 Spain: Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
- 11.1.29.1.1 Spain: Molecular Diagnostics Market, by Product and Services
- 11.1.29.1 Spain: Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
- 11.1.30 Spain: Molecular Diagnostics Market, by End User
- 11.1.31 Rest of Europe
- 11.1.31.1 Overview
- 11.1.32 Rest of Europe: Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.33 Rest of Europe: Molecular Diagnostics Market, by Disease Area
- 11.1.34 Rest of Europe: Molecular Diagnostics Market, by Technology
- 11.1.34.1 Rest of Europe: Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
- 11.1.35 Rest of Europe: Molecular Diagnostics Market, by Product and Services
- 11.1.36 Rest of Europe: Molecular Diagnostics Market, by End User
- 11.1.1 Overview
12. Europe Molecular Diagnostics Market Industry Landscape
- 12.1 Overview
- 12.2 Growth Strategies Done by the Companies in the Market (%)
- 12.3 Organic Developments
- 12.3.1 Overview
- 12.4 Inorganic Developments
- 12.4.1 Overview
13. Europe Molecular Diagnostics Market, Key Company Profiles
- 13.1 Abbott Laboratories
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
- 13.2 Agilent Technologies Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
- 13.3 Thermo Fisher Scientific Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 F. Hoffmann-La Roche Ltd
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
- 13.5 Qiagen NV
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
- 13.6 bioMerieux SA
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
- 13.7 Illumina Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 Danaher
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
- 13.9 Siemens Healthineers AG
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
- 13.10 Novartis AG
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
- 14.1 About Us
- 14.2 Glossary of Terms
